2018 American Transplant Congress
Association of Immunosuppressive Therapy Regimen with Sepsis Outcomes among Kidney Transplant Recipients
OBJECTIVE: Immunosuppressive therapy (IST) could impact sepsis outcomes by altering the host immune response. We examined the associations of IST regimens with sepsis outcomes among…2018 American Transplant Congress
Polyclonal Cellular Immune Function is Dose-Dependently Inhibited by Immunosuppressive Drugs but Has Limited Value in Predicting Infection or Rejection Episodes
1Saarland University, Homburg/Saar, Germany; 2Saarland University, Homburg/Saar, Germany.
Background: Dosage of immunosuppressive drugs in transplant patients must be balanced to prevent graft rejection and infectious complications. Knowledge on general immune function may therefore…2018 American Transplant Congress
Islet Xenotransplantation: A Quest for Clinically Available Immunosuppression Regimens
Department of Surgery, Duke University Medical Center, Durham, NC.
IntroductionThe field of porcine islet xenotransplantation has made significant progress in non-human primate studies in recent years. However, one major barrier preventing clinical translation of…2018 American Transplant Congress
Experience with Immunosuppressive Strategies in Vascularized Composite Allotransplantation of Face
This retrospective review of the largest face transplant cohort aims to describe the evolution of immunosuppressive (IS) regimens used in face transplant recipients.All face transplants…2018 American Transplant Congress
Tacrolimus Pharmacokinetics (PK) at Low, Medium, and High Trough Levels in Patients Converted from Twice-Daily Immediate-Release Tacrolimus (TacBID) to Once-Daily Extended-Release Tacrolimus (LCPT)
LCPT (Envarsus XR®) is a once-daily, extended-release formulation of tacrolimus which has demonstrated greater bioavailability and a smoother PK profile compared to TacBID. This post-hoc…2018 American Transplant Congress
Do We Need to Worry about EBV DNAemia in the Late Post-Transplant Period?
Background: Despite detectable Epstein-Barr virus (EBV) in blood, kidney transplant patients (KTR) may have no apparent clinical consequence. This study aims to explore the clinical…2018 American Transplant Congress
BK Viremia in Simultaneous Kidney Pancreas Recipients: Single Center Experience
Introduction: The impact of BK viremia in recipients of simultaneous pancreas and kidney transplantation (SPK) is not well known. We therefore studied the incidence and…2018 American Transplant Congress
Comparison of De Novo Rapamune versus Everolimus Maintenance Immunosuppression; an Interim Analysis
General Surgery, Ohio State University, Columbus, OH.
This is a 1 year interim analysis of the results of a 3 year, single center, randomized, prospective, open-label study comparing the efficacy and tolerability…2018 American Transplant Congress
Evaluation and Cost Burden of Inappropriately Drawn Immunosuppression Trough Levels in the Acute Care Setting at an Academic Medical Center
University of Virginia Health System, Charlottesville, VA.
Trough drug levels in narrow therapeutic index medications, such as CNI and mTOR inhibitors are used to estimate total drug exposure. Inappropriately measured trough levels…2018 American Transplant Congress
12-Months Evolution of Anti-HLA Antibodies Donor Specific Antibodies after Rescue Switch from CNi-Based Immunosuppressive Regimen to Belatacept in Kidney Allograft Recipients
IntroductionAfter kidney transplantation, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) leads to adverse effects, such as nephrotoxicity and proteinuria. Currently, available data…
- « Previous Page
- 1
- …
- 65
- 66
- 67
- 68
- 69
- …
- 138
- Next Page »